These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 8521758

  • 1. Guidelines for the use of propafenone in treating supraventricular arrhythmias.
    Kishore AG, Camm AJ.
    Drugs; 1995 Aug; 50(2):250-62. PubMed ID: 8521758
    [Abstract] [Full Text] [Related]

  • 2. Propafenone: an effective agent for the management of supraventricular arrhythmias.
    Grant AO.
    J Cardiovasc Electrophysiol; 1996 Apr; 7(4):353-64. PubMed ID: 8777484
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA, Kuhn RJ, McCaffrey FM.
    Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
    [Abstract] [Full Text] [Related]

  • 4. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.
    Bryson HM, Palmer KJ, Langtry HD, Fitton A.
    Drugs; 1993 Jan; 45(1):85-130. PubMed ID: 7680987
    [Abstract] [Full Text] [Related]

  • 5. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists.
    Janousek J, Paul T.
    Am J Cardiol; 1998 May 01; 81(9):1121-4. PubMed ID: 9605053
    [Abstract] [Full Text] [Related]

  • 6. Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
    Rae AP.
    Am J Cardiol; 1998 Oct 16; 82(8A):59N-65N. PubMed ID: 9809902
    [Abstract] [Full Text] [Related]

  • 7. Clinical experience with propafenone for cardiac arrhythmias in the young.
    Heusch A, Kramer HH, Krogmann ON, Rammos S, Bourgeous M.
    Eur Heart J; 1994 Aug 16; 15(8):1050-6. PubMed ID: 7527342
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.
    Luedtke SA, Kuhn RJ, McCaffrey FM.
    Ann Pharmacother; 1997 Oct 16; 31(10):1227-43. PubMed ID: 9337449
    [Abstract] [Full Text] [Related]

  • 9. Atrial fibrillation and the pharmacological treatment: the role of propafenone.
    Sestito A, Molina E.
    Eur Rev Med Pharmacol Sci; 2012 Feb 16; 16(2):242-53. PubMed ID: 22428477
    [Abstract] [Full Text] [Related]

  • 10. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
    Coumel P, Leclercq JF, Assayag P.
    Am J Cardiol; 1984 Nov 14; 54(9):60D-66D. PubMed ID: 6208770
    [Abstract] [Full Text] [Related]

  • 11. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Harron DW, Brogden RN.
    Drugs; 1987 Dec 14; 34(6):617-47. PubMed ID: 3322781
    [Abstract] [Full Text] [Related]

  • 12. Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.
    Capucci A, Boriani G.
    Drug Saf; 1995 Jan 14; 12(1):55-72. PubMed ID: 7741984
    [Abstract] [Full Text] [Related]

  • 13. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis.
    Reimold SC, Maisel WH, Antman EM.
    Am J Cardiol; 1998 Oct 16; 82(8A):66N-71N. PubMed ID: 9809903
    [Abstract] [Full Text] [Related]

  • 14. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H, Maison Blanche P, Marchand X, Canler A, Rouesnel P, Bleinc D, Péraudeau P, Scheck F.
    Ann Cardiol Angeiol (Paris); 1996 Oct 16; 45(8):469-79. PubMed ID: 8952741
    [Abstract] [Full Text] [Related]

  • 15. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, Kienzle MG.
    Am J Cardiol; 1996 Jan 25; 77(3):72A-82A. PubMed ID: 8607395
    [Abstract] [Full Text] [Related]

  • 16. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M, Cullen MT, Casadei G.
    Eur Heart J; 1995 Dec 25; 16(12):1943-51. PubMed ID: 8682031
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias.
    Reimer A, Paul T, Kallfelz HC.
    Am J Cardiol; 1991 Sep 15; 68(8):741-4. PubMed ID: 1892080
    [Abstract] [Full Text] [Related]

  • 18. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators.
    Stroobandt R, Stiels B, Hoebrechts R.
    Am J Cardiol; 1997 Feb 15; 79(4):418-23. PubMed ID: 9052343
    [Abstract] [Full Text] [Related]

  • 19. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
    Circulation; 1995 Nov 01; 92(9):2550-7. PubMed ID: 7586356
    [Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.
    Podrid PJ, Anderson JL.
    Am J Cardiol; 1996 Aug 15; 78(4):430-4. PubMed ID: 8752188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.